Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.91M | 18.46M | 18.59M | 13.70M | -5.88M |
| Total Depreciation and Amortization | 493.00K | 492.10K | 507.20K | 511.10K | 508.30K |
| Total Amortization of Deferred Charges | 3.50K | 3.50K | 3.50K | 3.50K | 3.50K |
| Total Other Non-Cash Items | 1.09M | -7.08M | -10.16M | -5.25M | 27.26M |
| Change in Net Operating Assets | 2.57M | -2.73M | -14.22M | -3.86M | -7.11M |
| Cash from Operations | 10.07M | 9.15M | -5.28M | 5.10M | 14.78M |
| Capital Expenditure | -809.00K | -398.00K | -206.10K | -103.30K | -218.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -809.00K | -398.00K | -206.10K | -103.30K | -218.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -118.60K | -120.10K | -123.80K | -266.50K | -4.13M |
| Issuance of Common Stock | 4.00K | 78.50K | 90.20K | 150.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -114.60K | -41.50K | -33.60K | -116.50K | -4.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.15M | 8.71M | -5.52M | 4.88M | 10.43M |